Overview
BMRN market data
Price History
BMRN price chart
Valuation & Profitability
- P/E (TTM)
- 182.98 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $1.77 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.23 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 2.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $49.26 – $70.98 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $13.4B · P/B 1.88 · P/S 3.92.
Company News
BioMarin Pharmaceutical shares are trading higher after Canaccord Genuity maintained its Buy rating on the stock and raised its price target from $111 to $114.Benzinga · Aug 10, 2026, 5:55 PM
CORRECTION: BioMarin Pharmaceutical Ticker Is "BMRN"Benzinga · Aug 10, 2026, 5:51 PM
Canaccord Genuity Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $114Benzinga · Aug 10, 2026, 12:15 PM
Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $124Benzinga · Aug 7, 2026, 6:48 PM
Oppenheimer Maintains Outperform on BioMarin Pharmaceutical, Raises Price Target to $97Benzinga · Aug 7, 2026, 1:51 PM
BioMarin Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 guidance. Also, HC Wainwright & Co raised its price target on the stock from $50 to $60.Benzinga · Aug 7, 2026, 11:26 AM
HC Wainwright & Co. Maintains Neutral on BioMarin Pharmaceutical, Raises Price Target to $60Benzinga · Aug 7, 2026, 11:04 AM
BioMarin Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 guidance.Benzinga · Aug 6, 2026, 8:30 PM
BioMarin Pharmaceutical Raises FY2026 Adj EPS Guidance from $4.85-$5.05 to $4.90-$5.10 vs $3.64 Est; Raises FY2026 Sales Guidance from $3.825B-$3.925B to $3.875B-$3.925B vs $3.875B EstBenzinga · Aug 6, 2026, 8:14 PM
Biomarin Pharmaceutical Q2 Adj. EPS $1.20 Beats $0.69 Estimate, Sales $990.000M Beat $926.908M EstimateBenzinga · Aug 6, 2026, 8:12 PM